These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 19948456

  • 21. mTOR inhibition in advanced renal cell carcinoma: which criteria should be used to evaluate therapeutic outcome?
    Eimer C, Gerullis H, Heuck C, Otto T.
    Anticancer Drugs; 2011 Jan; 22(1):18-23. PubMed ID: 21037468
    [Abstract] [Full Text] [Related]

  • 22. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
    Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP.
    Cancer; 2009 Jun 01; 115(11):2438-46. PubMed ID: 19306412
    [Abstract] [Full Text] [Related]

  • 23. Temsirolimus: a safety and efficacy review.
    Bukowski RM.
    Expert Opin Drug Saf; 2012 Sep 01; 11(5):861-79. PubMed ID: 22861825
    [Abstract] [Full Text] [Related]

  • 24. Temsirolimus in renal cell carcinoma.
    Otto T, Eimer C, Gerullis H.
    Transplant Proc; 2008 Dec 01; 40(10 Suppl):S36-9. PubMed ID: 19100905
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.
    Grgic T, Mis L, Hammond JM.
    Ann Pharmacother; 2011 Jan 01; 45(1):78-83. PubMed ID: 21177421
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Targeting mTOR in renal cell carcinoma.
    Hudes GR.
    Cancer; 2009 May 15; 115(10 Suppl):2313-20. PubMed ID: 19402072
    [Abstract] [Full Text] [Related]

  • 31. Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma.
    Bourdeanu L, Twardowski P, Pal SK.
    Clin J Oncol Nurs; 2011 Oct 15; 15(5):513-7. PubMed ID: 21951737
    [Abstract] [Full Text] [Related]

  • 32. [Antitumoral effect of proliferation signal inhibitors].
    Dumortier J.
    Gastroenterol Clin Biol; 2009 Nov 15; 33 Suppl 4():S263-7. PubMed ID: 20004333
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program.
    van den Eertwegh AJ, Karakiewicz P, Bavbek S, Rha SY, Bracarda S, Bahl A, Ou YC, Kim D, Panneerselvam A, Anak O, Grünwald V.
    Urology; 2013 Jan 15; 81(1):143-9. PubMed ID: 23273080
    [Abstract] [Full Text] [Related]

  • 36. How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma.
    Escudier B.
    J Clin Oncol; 2010 May 01; 28(13):2125-6. PubMed ID: 20368540
    [No Abstract] [Full Text] [Related]

  • 37. Selected toxicities of targeted therapies: presentation and management.
    Kollmannsberger C, Mitchell T.
    Semin Oncol; 2013 Aug 01; 40(4):499-510. PubMed ID: 23972714
    [Abstract] [Full Text] [Related]

  • 38. Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors.
    Bukowski RM.
    Clin Genitourin Cancer; 2007 Sep 01; 5(6):359-61. PubMed ID: 17956708
    [No Abstract] [Full Text] [Related]

  • 39. [Adverse events associated with temsirolimus for patients with metastatic renal cell carcinoma].
    Miyake H, Fujisawa M.
    Hinyokika Kiyo; 2012 Nov 01; 58(11):651-4. PubMed ID: 23254795
    [Abstract] [Full Text] [Related]

  • 40. ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma.
    Roulin D, Demartines N, Dormond O.
    Biochem Soc Trans; 2011 Apr 01; 39(2):492-4. PubMed ID: 21428926
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.